Diligence memo · auto-generated · as of July 2, 2026
Jaguar Health, Inc.
Jaguar Health, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Jaguar Health, Inc. operates in Pharmaceuticals, based in San Francisco.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Jaguar Health, Inc. has raised $43M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $41M on 2026-07-01.
Most recent recorded round closed around 2026-07-01.
Valuation (modeled)modeled
Provath models Jaguar Health, Inc. at approximately $178M (range $133M–$206M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.19× the median modeled value of Series C Pharmaceuticals companies in 2025–2027 (26 peers) — value vs value, same stage and era. Within the normal band (119% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise under a month ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 20.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 79% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 67% of those peers.
Closest niche peers: BlossomHill Therapeutics, Inc., Rivus Pharmaceuticals, Inc., Sparrow Pharmaceuticals, Inc., Arthrosi Therapeutics, Inc., Altesa BioSciences, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.